Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 106 Novo Nordisk maintains leadership within growth disorder Development in global growth disorder market DKK billion 20 15 10- 5 0 Aug 2013 - MAT volume kg CAGR volume¹: 17.5% CAGR value DKK¹: 13.3% 1 CAGR for 5-year period Source: IQVIA monthly MAT Aug, 2018 volume figures and value (DKK) figures changing diabetes® Growth disorder volume market share MAT value DKK kg 120 50% 100 40% 80 30% +60 20% 40 10% 20 0 0% Aug 2018 Aug 2013 Novo Nordisk Eli Lilly Source: IQVIA monthly MAT Aug, 2018 volume figures Note: Does not add up to 100% due to rounding Pfizer Merck Kgaa Sandoz - Other 26% 24% 14% 14% 9% 9% Aug 2018 novo nordisk

View entire presentation